ArticleFrontiers in medicine2024
Development of digital therapeutics in Hwa-byung treatment: exploring innovation potential in Korean medicine through practitioner survey.
Article in Frontiers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Digital Therapeutic for Hwa-Byung (Korean Culture-Related Anger Syndrome) Based on Acceptance and Commitment Therapy: A Pilot Feasibility Trial.Healthcare (Basel, Switzerland) · 2026Article
- User Experience and Clinical Utility of a Smartphone-Based Application for Hwa-Byung Treatment: a protocol for a single-arm prospective pilot study.Journal of pharmacopuncture · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hwa-byung (HB) is a culture-bound anger syndrome prevalent in Korea. While clinical practice guidelines emphasize mind-body modalities (MBMs) and psychotherapies for HB treatment, their implementation in Korean medicine (KM) remains unexplored. Digital therapeutics (DTx) offers potential solutions for treatment delivery barriers. This study investigated current HB treatment practices among KM doctors and their perceptions on DTx implementation. Methods: A nationwide web-based survey of licensed KMDs ( Results: Most KMDs utilized conventional KM treatments (acupuncture 95.4%, herbal medicine 94.0%), while MBMs (26.2%) and psychotherapies (21.3%) were underutilized despite their recognized importance. Primary barriers included time constraints (65.8%) and insufficient knowledge (62.9%). Treatment typically required 15.6 ± 60.7 weeks with 21.6 ± 37.4 sessions. While DTx knowledge was limited (mean score 2.3 ± 0.9/5), most KMDs (70.6%) expressed interest in DTx development, with 65.4% willing to implement it in practice. The estimated appropriate cost for HB DTx was 24,441.5 ± 13,566.0 KRW per session. Conclusion: This study reveals a significant gap between guidelines and clinical practice in HB treatment, particularly in implementing MBMs and psychotherapies. The positive attitude toward DTx suggests its potential as a practical solution to bridge this gap by providing accessible, standardized delivery of evidence-based psychological interventions within existing clinical workflows. Future DTx development should focus on addressing identified barriers while maintaining alignment with KM principles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.